Affymetrix (Santa Clara, California) Launches Solution To Enable Cancer Researchers To Rapidly Map The Functional Impact Of DNA Alterations On Gene Expression Profiles To Identify Potential Cancer Driver Events

SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix (NASDAQ:AFFX) announced today the launch of Concurrent Molecular Analysis Profiling (CoMAP™) capability, which enables cancer researchers to gain rapid insight into the functional impact of DNA copy number alterations by combining whole-genome copy number data with gene expression profiles to easily and cost-effectively visualize and identify cancer driver events.

Help employers find you! Check out all the jobs and post your resume.